查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1447727

慢性鼻竇炎伴隨鼻息肉 (CRSwNP) 市場評估：按治療類型、給藥途徑、分銷管道和地區劃分的機會和預測（2017-2031 年）

Chronic Rhinosinusitis With Nasal Polyps Market Assessment, By Treatment Type, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 228 Pages | 商品交期: 3-5個工作天內

價格

全球慢性鼻竇炎伴隨鼻息肉 (CRSwNP) 市場規模預計將從 2023 年的 35.4 億美元增長至 2031 年，2024-2031 年預測期間複合年增長率為 6.33%，預計將增長至 57.8 億美元。

由於人口老化、空氣污染、過度吸菸等諸多原因，慢性鼻竇炎的盛行率預計將持續上升，市場也有望隨之成長。 針對特定發炎途徑治療慢性鼻竇炎伴隨鼻息肉（CRSwNP）的生物製劑的開發和監管批准是市場成長的主要驅動力。 由於人們對該疾病和可用治療方法的認識不斷提高，預計該市場也會成長。 特別是 Fasenra（benralizumab）、TEZSPIRE（tezepelumab）和 Depemokimab/GSK3511294 等新藥物預計將推動市場發展。

慢性鼻竇炎伴隨鼻息肉 (CRSwNP) 的盛行率不斷增加

CRSwNP 的盛行率持續增加。 患有氣喘和/或非類固醇抗發炎藥物引起的呼吸道疾病惡化（NSAID-ERD）的患者以及需要全身性皮質類固醇重複治療和/或手術的患者的疾病負擔特別高。 CRSwNP 患者的症狀包括鼻漏、鼻塞和嗅覺喪失，這會損害身心健康，包括睡眠品質。 針對鼻息肉和慢性鼻竇炎的潛在過程的治療在醫學上是必要的。 領先的公司正在推廣和銷售新的、耐受性良好的治療方法，這些治療方法可以有效控制症狀並最大限度地降低鼻息肉的復發率，以滿足需求。

本報告調查了全球慢性鼻竇炎伴隨鼻息肉(CRSwNP) 市場，提供了市場定義和概述、市場規模趨勢和預測、各個細分市場和地區的詳細分析、行業結構，總結了影響市場成長因素的分析，案例研究、競爭格局和主要公司簡介。

目錄

第1章研究方法

第 2 章專案範圍與定義

第 3 章執行摘要

第4章全球慢性鼻竇炎伴隨鼻息肉（CRSwNP）市場展望

  • 市場規模/預測
  • 依治療類型
    • 藥物
    • 手術
  • 依給藥途徑
    • 鼻音
    • 口頭
    • 其他
  • 按分銷管道
    • 醫院藥房
    • 零售藥局
    • 網路藥局
  • 按地區
    • 北美
    • 歐洲
    • 南美洲
    • 亞太地區
    • 中東/非洲
  • 各公司的市佔率

第5章全球慢性鼻竇炎伴隨鼻息肉 (CRSwNP) 市場展望（按地區）

  • 北美
  • 歐洲
  • 南美洲
  • 亞太地區
  • 中東/非洲

第 6 章市場映射

  • 依治療類型
  • 依給藥途徑
  • 按分銷管道
  • 按地區

第7章宏觀環境與產業結構

  • 需求與供給分析
  • 匯入/匯出分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市場動態

  • 生長促進因素
  • 抑制生長的因素（問題/抑制因素）

第 9 章監理架構與創新

  • 臨床試驗
  • 專利情況
  • 監理機關的核准
  • 創新/新興技術

第10章主要公司狀況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 位市場領導者的市場收入分析
  • 併購/合資企業（如果適用）
  • SWOT 分析（主要公司）
  • 專利分析（如果適用）

第11章價格分析

第 12 章案例研究

第13章主要公司展望

  • AstraZeneca plc
  • Amgen Inc
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Regeneron Pharmaceuticals Inc
  • Optinose US Inc.
  • Genentech USA, Inc.
  • Novartis Pharmaceuticals Corporation
  • Medtronic plc (Intersect ENT, Inc.)
  • Lyra Therapeutics, Inc.

第 14 章策略建議

第15章關於我們公司/免責聲明

Product Code: MX11134

Chronic rhinosinusitis with nasal polyps (CRSwNP) market is projected to witness a CAGR of 6.33% during the forecast period 2024-2031, growing from USD 3.54 billion in 2023 to USD 5.78 billion in 2031F.

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a condition characterized by persistent inflammation of the sinuses and the presence of benign inflammatory lesions called nasal polyps. These polyps typically develop in the ethmoid sinuses and can obstruct the nasal airways, leading to various symptoms such as facial pressure or pain, nasal congestion, hyposmia or anosmia (reduced or complete lack of smell), and postnasal drip.

The market is anticipated to grow under the influence of the growing prevalence of chronic rhinosinusitis which is anticipated to keep rising due to the increasing geriatric population, air pollution, excessive smoking, and many other reasons. The development of biologic therapies targeting specific inflammatory pathways for the treatment of chronic rhinosinusitis with nasal polyps and their regulatory approvals have significantly enhanced the growth of the market. The market is expected to grow due to the increasing awareness about disease and its available treatments. The market is expected to be driven by emerging drugs such as FASENRA (benralizumab), TEZSPIRE (tezepelumab), and Depemokimab/GSK3511294 among other factors. The development and manufacturing of proficient sinusitis drugs, despite the stringent approval process and time-consuming clinical trials are some of the major factors hampering the growth of the market.

In March 2023, Optinose announced that its supplemental new drug application (sNDA) for XHANCE has been accepted for review by the US FDA. XHANCE is a drug-device combination product that utilizes the Exhalation Delivery System (EDS) to deliver fluticasone propionate, a widely used nasal anti-inflammatory drug, high and deep into difficult-to-access sinuses and sinonasal drainage tracts. The sNDA submission is based on the results of two Phase 3 clinical trials from the ReOpen Program, which studied the treatment of chronic sinusitis.

Growing Prevalence of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

The prevalence of CRSwNP is consistently increasing. The disease burden is particularly high in patients with comorbid asthma and/or nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (NSAID-ERD) and in patients who need repeated treatment with systemic corticosteroids and/or surgery. Symptoms in CRSwNP patients include rhinorrhea, nasal congestion, and loss of smell. These symptoms impair both physical and mental health, including the quality of sleep. Targeted treatment of nasal polyps and the underlying processes of chronic sinus inflammation are medically necessary. Novel, well-tolerated therapies that provide effective symptom control minimize recurrence rates of nasal polyps being promoted and marketed by key players to cater to the requirements.

According to an article published in 'Allergy, Asthma & Clinical Immunology' journal in December 2023, chronic rhinosinusitis is estimated to affect about 2 to 14% of the United States population, out of which about 25 to 30% of cases are associated with the presence of nasal polyps (CRSwNP).

Clinical Developments for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Chronic rhinosinusitis with nasal polyps (CRSwNP) is usually associated with asthma and allergic rhinitis. Diagnosis of CRSwNP is done by bilateral endoscopic visualization of polyps in the nasal area. Treatment options for CRSwNP include topical irrigation and intranasal corticosteroids, systemic corticosteroids, monoclonal antibodies, surgery, and biological therapies targeting underlying inflammatory processes. Additionally, targeting the underlying inflammatory pathways involved in the pathophysiology of CRSwNP, and offering new treatment options for patients with more severe or unresponsive diseases have been significant milestones for the treatment of CRSwNP. The role of biologics and corticosteroids in the market and advancements in these drug categories are anticipated to drive growth in the market. Various promising products in the clinical pipeline seem to contribute to the market expansion.

For instance, GSK's Depemokimab (GSK3511294) is a pipeline drug that is expected to complete phase III clinical trials in the third quarter of the year 2024 and has shown significant efficacy in phase I and II clinical trials. Similarly, in January 2024, Upstream Bio announced the entry in phase II clinical trial and the beginning of dosing the first patients with Verekitug (UPB-101) for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP).

Dominance of Medications Segment

Medications are generally preferred over surgery for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), thus the segment dominates the market landscape. Medication allows for long-term management, helping to maintain remission and prevent recurrences. They minimize invasive procedures, especially when patients do not meet strict surgical requirements or if their symptoms remain controlled with pharmacotherapy. Medical treatment improves quality of life by allowing patients to manage their symptoms while avoiding complications associated with surgery. Medications are less expensive and easily available, and they are cost-effective options.

Although surgery may be required in several cases as medication dominates the market. The government initiatives to reduce the disease burden through subsidies and reimbursements might help in further expansion of the market.

For instance, in April 2023, Nucala became the first monoclonal antibody to be PBS-subsidized by the Australian government for the treatment of CRSwNP. Nucala is the product of GSK plc marketed since 2015. The initiative by the Australian government is anticipated to provide subsidized access to this new treatment option for CRSwNP patients.

Nasal Route of Administration to be the Leading Segment

The nasal route of administration is preferred for medications of chronic rhinosinusitis with nasal polyposis (CRSwNP) as it provides an easy and fast route for local treatment of nose and sinus diseases with lower doses than systemic administration and fewer adverse effects. For instance, intranasal corticosteroids, such as mometasone furoate nasal spray (MFNS), are the preferred treatment for CRSwNP. Other treatments that can be administered intranasally for CRSwNP include intranasal anticholinergic agents, intranasal cromones, and nasal saline. Several marketed products in the form of nasal inhalation and sprays are available for the treatment of CRSwNP. Expanding the scope of indication for already approved drugs for CRSwNP, promising a step of revenue generation for key players.

For instance, in January 2024, Regeneron Pharmaceuticals, Inc. and Sanofi announced that the US Food and Drug Administration approved Dupixent (dupilumab) for the treatment of pediatric patients of age 1 to 11 years, and weight of at least 15 kg, suffering from eosinophilic esophagitis (EoE). Dupixent became the first medication approved in the United States specifically to treat these patients. The approval expands the approved indication of Dupixent including atopic dermatitis, chronic rhinosinusitis with nasal polyposis, prurigo nodularis, asthma, and EoE.

North America to be the Dominating Region

North America is anticipated to be the leading region in the market with a higher value share. The prevalence of chronic rhinosinusitis with nasal polyps (CRSwNP) in the United States is estimated to be around 2-14% as per various studies. The prevalence of CRSwNP is greater in men than in women. Asthma, allergy, and allergic rhinitis are the most common comorbidities associated with CRSwNP and the high occurrence of these conditions in North America increases the risk of CRSwNP. Obesity is one of the major risk factors for CRSwNP and more than 40% of the United States population is obese, further increasing the risk of CRSwNp.

Additionally, the strong presence of key market players in the region and the strong clinical pipeline for the treatment option for CRSwNP strengthens the lead position of North America. Regulatory emphasis on reducing the disease burden of CRSwNP is expected to expand the market.

For instance, in June 2023, the US Food and Drug Administration made its final industry guidelines titled "Developing Drugs for Treatment of Chronic Rhinosinusitis With Nasal Polyps" public. The guideline is intended to support sponsors in the creation of pharmaceuticals or biological products intended to treat nasal polyps and chronic rhinosinusitis (CRSwNP).

Future Market Scenario

The major factor driving the future market scenario is the growing prevalence of chronic rhinosinusitis due to the rising aging population, pollution levels, and smoking tendencies of individuals. Aging and other comorbidities like asthma significantly increase the risk of disease occurrence.

The development of medications for CRSwNP by exploring alternative

inflammatory pathways such as interleukins 4, 5, 13, 33, ILC2 cells, and IgE along with other pathogenic mechanisms involved in CRS pathogenesis such as arachidonic acid pathway, extravascular fibrin deposition (coagulation cascade), and B-cell dysregulation, can open the market with newer and more effective drug candidates. For instance, Benralizumab is a promising drug candidate for AstraZeneca undergoing phase III clinical investigations which is expected to be completed in the early months of 2025.

Key Players Landscape and Outlook

Market players like Sanofi, Regeneron Pharmaceuticals, and GlaxoSmithKline have several promising products in the clinical pipeline which shows the market readiness of these companies. The regulatory approvals and expansion in approved indications for biologics are anticipated to divert the attention of key players for the development of further biologics and biosimilar products in the forecast years.

In January 2024, GSK plc and Aiolos Bio, Inc. announced an agreement under which GSK acquired Aiolos. Aiolos is a clinical-stage biopharmaceutical company focused on the unmet treatment needs of patients with specific respiratory and inflammatory conditions. The deal was valued at USD 1.4 billion. The acquisition enables GSK with access to Aiolos' AIO-001, which is a long-acting anti-thymic stromal lymphopoietin monoclonal antibody prepared to enter phase 2 clinical trials for the treatment of adult asthma patients, with the potential for additional indications including chronic rhinosinusitis with nasal polyps.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Outlook, 2017-2031F

  • 4.1.Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2.By Treatment Type
    • 4.2.1.Medications
      • 4.2.1.1.Corticosteroids
      • 4.2.1.2.Biologics
      • 4.2.1.2.1.Dupilumab (Dupixent)
      • 4.2.1.2.2.Omalizumab (Xolair)
      • 4.2.1.2.3.Mepolizumab (Nucala)
      • 4.2.1.3.Antibiotics
      • 4.2.1.4.Antifungal Drugs
    • 4.2.2.Surgical Methods
  • 4.3.By Route of Administration
    • 4.3.1.Nasal
    • 4.3.2.Oral
    • 4.3.3.Others
  • 4.4.By Distribution Channel
    • 4.4.1.Hospital Pharmacies
    • 4.4.2.Retail Pharmacies
    • 4.4.3.Online Pharmacies
  • 4.5.By Region
    • 4.5.1.North America
    • 4.5.2.Europe
    • 4.5.3.Asia-Pacific
    • 4.5.4.South America
    • 4.5.5.Middle East and Africa
  • 4.6.By Company Market Share (%), 2023

5.Global Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Outlook, By Region, 2017-2031F

  • 5.1.North America*
    • 5.1.1.Market Size & Forecast
      • 5.1.1.1.By Value
      • 5.1.1.2.By Volume
    • 5.1.2.By Treatment Type
      • 5.1.2.1.Medications
      • 5.1.2.1.1.Corticosteroids
      • 5.1.2.1.2.Biologics
      • 5.1.2.1.2.1.Dupilumab (Dupixent)
      • 5.1.2.1.2.2.Omalizumab (Xolair)
      • 5.1.2.1.2.3.Mepolizumab (Nucala)
      • 5.1.2.1.3.Antibiotics
      • 5.1.2.1.4.Antifungal Drugs
      • 5.1.2.2.Surgical Methods
    • 5.1.3.By Route of Administration
      • 5.1.3.1.Nasal
      • 5.1.3.2.Oral
      • 5.1.3.3.Others
    • 5.1.4.By Distribution Channel
      • 5.1.4.1.Hospital Pharmacies
      • 5.1.4.2.Retail Pharmacies
      • 5.1.4.3.Online Pharmacies
    • 5.1.5.United States*
      • 5.1.5.1.Market Size & Forecast
      • 5.1.5.1.1.By Value
      • 5.1.5.1.2.By Volume
      • 5.1.5.2.By Treatment Type
      • 5.1.5.2.1.Medications
      • 5.1.5.2.1.1.Corticosteroids
      • 5.1.5.2.1.2.Biologics
      • 5.1.5.2.1.2.1.Dupilumab (Dupixent)
      • 5.1.5.2.1.2.2.Omalizumab (Xolair)
      • 5.1.5.2.1.2.3.Mepolizumab (Nucala)
      • 5.1.5.2.1.3.Antibiotics
      • 5.1.5.2.1.4.Antifungal Drugs
      • 5.1.5.2.2.Surgical Methods
      • 5.1.5.3.By Route of Administration
      • 5.1.5.3.1.Nasal
      • 5.1.5.3.2.Oral
      • 5.1.5.3.3.Others
      • 5.1.5.4.By Distribution Channel
      • 5.1.5.4.1.Hospital Pharmacies
      • 5.1.5.4.2.Retail Pharmacies
      • 5.1.5.4.3.Online Pharmacies
    • 5.1.6.Canada
    • 5.1.7.Mexico

All segments will be provided for all regions and countries covered

  • 5.2.Europe
    • 5.2.1.Germany
    • 5.2.2.France
    • 5.2.3.Italy
    • 5.2.4.United Kingdom
    • 5.2.5.Russia
    • 5.2.6.Netherlands
    • 5.2.7.Spain
    • 5.2.8.Turkey
    • 5.2.9.Poland
  • 5.3.Asia-Pacific
    • 5.3.1.India
    • 5.3.2.China
    • 5.3.3.Japan
    • 5.3.4.Australia
    • 5.3.5.Vietnam
    • 5.3.6.South Korea
    • 5.3.7.Indonesia
    • 5.3.8.Philippines
  • 5.4.South America
    • 5.4.1.Brazil
    • 5.4.2.Argentina
  • 5.5.Middle East & Africa
    • 5.5.1.Saudi Arabia
    • 5.5.2.UAE
    • 5.5.3.South Africa

6.Market Mapping, 2023

  • 6.1.By Treatment Type
  • 6.2.By Route of Administration
  • 6.3.By Distribution Channel
  • 6.4.By Region

7.Macro Environment and Industry Structure

  • 7.1.Demand Supply Analysis
  • 7.2.Import Export Analysis
  • 7.3.Value Chain Analysis
  • 7.4.PESTEL Analysis
    • 7.4.1.Political Factors
    • 7.4.2.Economic System
    • 7.4.3.Social Implications
    • 7.4.4.Technological Advancements
    • 7.4.5.Environmental Impacts
    • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5.Porter's Five Forces Analysis
    • 7.4.7.Supplier Power
    • 7.4.8.Buyer Power
    • 7.4.9.Substitution Threat
    • 7.4.10.Threat from New Entrant
    • 7.4.11.Competitive Rivalry

8.Market Dynamics

  • 8.1.Growth Drivers
  • 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

  • 9.1.Clinical Trials
  • 9.2.Patent Landscape
  • 9.3.Regulatory Approvals
  • 9.4.Innovations/Emerging Technologies

10.Key Players Landscape

  • 10.1.Competition Matrix of Top Five Market Leaders
  • 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4.SWOT Analysis (For Five Market Players)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

  • 13.1.AstraZeneca plc
    • 13.1.1.Company Details
    • 13.1.2.Key Management Personnel
    • 13.1.3.Products & Services
    • 13.1.4.Financials (As reported)
    • 13.1.5.Key Market Focus & Geographical Presence
    • 13.1.6.Recent Developments
  • 13.2.Amgen Inc
  • 13.3.GlaxoSmithKline plc
  • 13.4.Sanofi S.A.
  • 13.5.Regeneron Pharmaceuticals Inc
  • 13.6.Optinose US Inc.
  • 13.7.Genentech USA, Inc.
  • 13.8.Novartis Pharmaceuticals Corporation
  • 13.9.Medtronic plc (Intersect ENT, Inc.)
  • 13.10.Lyra Therapeutics, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.Global Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 2.Global Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 3.Global Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 4.Global Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 5.Global Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 6.Global Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Region, 2017-2031F
  • Figure 7.North America Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 8.North America Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 9.North America Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 10.North America Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 11.North America Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 12.North America Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Country, 2017-2031F
  • Figure 13.United States Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 14.United States Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 15.United States Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 16.United States Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 17.United States Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 18.Canada Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 19.Canada Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 20.Canada Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 21.Canada Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 22.Canada Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 23.Mexico Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 24.Mexico Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 25.Mexico Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 26.Mexico Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 27.Mexico Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 28.Europe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 29.Europe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 30.Europe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 31.Europe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 32.Europe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 33.Europe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Country, 2017-2031F
  • Figure 34.Germany Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 35.Germany Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 36.Germany Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 37.Germany Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 38.Germany Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 39.France Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 40.France Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 41.France Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 42.France Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 43.France Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 44.Italy Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 45.Italy Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 46.Italy Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 47.Italy Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 48.Italy Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 49.United Kingdom Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 50.United Kingdom Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 51.United Kingdom Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 52.United Kingdom Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 53.United Kingdom Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 54.Russia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 55.Russia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 56.Russia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 57.Russia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 58.Russia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 59.Netherlands Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 60.Netherlands Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 61.Netherlands Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 62.Netherlands Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 63.Netherlands Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 64.Spain Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 65.Spain Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 66.Spain Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 67.Spain Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 68.Spain Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 69.Turkey Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 70.Turkey Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 71.Turkey Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 72.Turkey Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 73.Turkey Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 74.Poland Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 75.Poland Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 76.Poland Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 77.Poland Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 78.Poland Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 79.South America Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 80.South America Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 81.South America Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 82.South America Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 83.South America Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 84.South America Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Country, 2017-2031F
  • Figure 85.Brazil Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 86.Brazil Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 87.Brazil Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 88.Brazil Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 89.Brazil Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 90.Argentina Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 91.Argentina Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 92.Argentina Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 93.Argentina Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 94.Argentina Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 95.Asia-Pacific Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 96.Asia-Pacific Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 97.Asia-Pacific Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 98.Asia-Pacific Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 99.Asia-Pacific Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 100.Asia-Pacific Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Country, 2017-2031F
  • Figure 101.India Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 102.India Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 103.India Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 104.India Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 105.India Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 106.China Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 107.China Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 108.China Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 109.China Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 110.China Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 111.Japan Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 112.Japan Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 113.Japan Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 114.Japan Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 115.Japan Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 116.Australia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 117.Australia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 118.Australia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 119.Australia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 120.Australia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 121.Vietnam Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 122.Vietnam Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 123.Vietnam Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 124.Vietnam Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 125.Vietnam Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 126.South Korea Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 127.South Korea Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 128.South Korea Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 129.South Korea Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 130.South Korea Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 131.Indonesia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 132.Indonesia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 133.Indonesia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 134.Indonesia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 135.Indonesia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 136.Philippines Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 137.Philippines Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 138.Philippines Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 139.Philippines Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 140.Philippines Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 141.Middle East & Africa Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 142.Middle East & Africa Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 143.Middle East & Africa Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 144.Middle East & Africa Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 145.Middle East & Africa Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 146.Middle East & Africa Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Country, 2017-2031F
  • Figure 147.Saudi Arabia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 148.Saudi Arabia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 149.Saudi Arabia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 150.Saudi Arabia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 151.Saudi Arabia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 152.UAE Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 153.UAE Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 154.UAE Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 155.UAE Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 156.UAE Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 157.South Africa Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
  • Figure 158.South Africa Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
  • Figure 159.South Africa Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 160.South Africa Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 161.South Africa Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 162.By Treatment Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163.By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164.By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023